Clinical trials: Positron-Emission Tomography
Alzheimer's Disease
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.
- Trial name
- NCT01703702
- Testing
- florbetapir (18F)
- Where
- 57 sites in United States, France and 1 more
- Volunteers
- 641 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
18F-AV-1451 Autopsy Study
This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.
- Trial name
- NCT02516046
- Testing
- Flortaucipir F18, PET Scan
- Where
- 31 sites in United States, Australia
- Volunteers
- 156 people
- Sponsor
- Avid Radiopharmaceuticals
Coronary Artery Disease
Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI
The study will evaluate the use of Flurpiridaz F18 injection in patients with CAD to determine if the study drug in PET imaging is better than SPECT imaging currently used for this purpose.
- Trial name
- NCT01681524
- Testing
- Flurpiridaz F18
- Sponsor
- Lantheus Medical Imaging
Renal Cell Carcinoma, Kidney Cancer
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
- Trial name
- NCT00606632
- Testing
- 124-Iodine-cG250 (124I-cG250), CT
- Where
- 14 sites in United States
- Volunteers
- 226 people
- Sponsor
- Heidelberg Pharma AG
Prostate Cancer
Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer
The goal of this clinical trial is to evaluate the diagnostic performance and safety of Flotufolastat F-18 injection PET imaging in prostate cancer subjects with biochemical recurrence following prior treatment.
- Trial name
- NCT07115277
- Testing
- Flotufolastat F-18 Injection
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Sinotau Pharmaceutical Group
Healthy
A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
The main objective of this trial is to investigate the effect of multiple oral dosing of high dose BI 1467335 over 28 days and multiple oral dosing of low dose BI 1467335 over 42 days on MAO-B occupancy in the brain compared to…
- Trial name
- NCT03927209
- Testing
- BI 1467335
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON…
- Trial name
- NCT06750419
- Testing
- 89Zr-TLX250 PET/CT
- Where
- 8 sites in China
- Volunteers
- 82 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer, Prostate Adenocarcinoma
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
- Trial name
- Solar-Recur (NCT06235099)
- Testing
- Copper Cu 64 PSMA I&T
- Where
- 31 sites in United States
- Volunteers
- 235 people
- Sponsor
- Curium US LLC
Parkinson's Disease
PET Study in Parkinson's Disease Patients
This is a multi-centre study to be conducted in Sweden and Finland. Up to 24 male and/or female patients of non-childbearing potential aged 45 to 75 years (inclusive), with a clinical diagnosis Parkinson's Disease will be…
- Trial name
- NCT01527695
- Testing
- ER tablet 25 mg AZD3241, ER tablet 100 mg AZD3241
- Where
- 3 sites in Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Ischemic Heart Disease (IHD)
XTR003 PET Radiotracer for the Detection of Viable Myocardium
The study was designed to explore the clinical feasibility of XTR003, a PET myocardial fatty-acid tracer, for the detection of viable myocardium in patients with ischemic heart disease (IHD).
- Trial name
- NCT05885854
- Testing
- XTR003
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sinotau Pharmaceutical Group
Neuroblastoma
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma
- Trial name
- NCT04724369
- Testing
- 18F-MFBG
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Neuroendocrine Neoplasms
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
The purpose of this study was to evaluate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in…
- Trial name
- NCT06240741
- Testing
- [68Ga]Ga-DOTA-TATE, 68Ge/68Ga Generator
- Where
- 8 sites in Japan
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Marginal Zone Lymphoma
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission…
- Trial name
- LYMFOR (NCT06125028)
- Testing
- [68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose
- Where
- 12 sites in Austria, France and 3 more
- Volunteers
- 8 people
- Sponsor
- Pentixapharm AG
Healthy
A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants
This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to about 10 weeks.
- Trial name
- NCT04392271
- Testing
- LY3372689, [18F]LSN3316612
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Solid Tumor, Positron-Emission Tomography(PET)
Phase I Clinical Trial of 68Ga-NOTA-SNA002
The clinical trial was a single-center, dose-increasing, open trial.In this clinical trial, 68Ga-NOTA-SNA002 was injected intravenously to observe its safety tolerance, radiation absorption dose, distribution characteristics…
- Trial name
- NCT05989997
- Testing
- 68Ga-NOTA-SNA002
- Where
- China
- Volunteers
- 17 people
- Sponsor
- SmartNuclide Biopharma
Coronary Artery Disease
A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography…
- Trial name
- NCT01347710
- Testing
- Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin)
- Where
- 81 sites in United States, Canada and 2 more
- Volunteers
- 795 people
- Sponsor
- Lantheus Medical Imaging
Coronary Artery Disease
Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia
Binodenoson (an experimental drug) and adenosine (an FDA-approved drug that is currently used by doctors) are used to increase blood flow to the heart just like when a person exercises on a treadmill.
- Trial name
- VISION-305 (NCT00944970)
- Testing
- binodenoson, adenosine
- Volunteers
- 578 people
- Sponsor
- Pfizer
Colorectal Cancer
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
The purpose of this study was to determine the activity of two doses of robatumumab (SCH 717454, MK-7454) in participants with relapsed or recurrent colorectal cancer.
- Trial name
- NCT00551213
- Testing
- Robatumumab, Irinotecan, Cetuximab
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Essential Thrombocythemia, Primary Myelofibrosis, Fibrotic Stage
18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia
The main purpose of this project is to study the uptake pattern of FLT-PET in cases, and it is value in assessing the malignant hematopoiesis in cases of Pre-PMF and ET, regarding diagnosis, staging and monitoring response to…
- Conditions
- Essential Thrombocythemia, Primary Myelofibrosis, Fibrotic Stage, Primary Myelofibrosis, Prefibrotic Stage
- Trial name
- PMF/ET-FLT (NCT03116542)
- Testing
- Diagnostic (18F-FLT PET/CT)
- Where
- Qatar
- Volunteers
- 21 people
- Sponsor
- Hamad Medical Corporation
Depressive Disorder
An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands
GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin. This is a single dose PET study in healthy subjects.A final analyses of safety data following exposure to single oral…
- Trial name
- NCT01153802
- Testing
- GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline